

NCIC CLINICAL TRIALS GROUP

MELANOMA

DISEASE SITE COMMITTEE MEETING AGENDA

(OPEN)

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: SCOTT

SUNDAY, APRIL 28, 2013 – 8:00 AM – 11:15 AM

CHAIR: TERESA PETRELLA, ALAN SPATZ

8:00 – 10:00 am	Welcome and Approval of Minutes	T. Petrella
	CME goals/objectives	T. Petrella/ Alan Spatz
	<ul style="list-style-type: none">• Overview of immunotherapy for melanoma and mechanism of action and activity of PD1	Omid Hamid
	<ul style="list-style-type: none">• Update of clinical trials and emerging results of anti-CTLA-4 agents	Michael Smylie
	<ul style="list-style-type: none">• Management strategies for adverse events for immunotherapies	Scott Ernst
	<ul style="list-style-type: none">• Round table future directions	All
10:00 – 10:15 am	BREAK	
10:15-10:30 am	TRIAL UPDATES:	
	NCIC CTG IND.202	Teresa Petrella
	NCIC CTG MEC.3 / ECOG 1609	Teresa Petrella
	NCIC CTG ME.11 / EORTC 18081	Teresa Petrella
10:30 – 11:15 am	NEW TRIAL PROPOSALS:	
	Radiation + GSK targeted inhibitor for brain metastases	Teresa Petrella/ Arjun Sahgal
	Phase 2 trial of TH302	Anthony Joshua
	Surgical resection trial	Francis Wright/ Marc Moncrieff
	OTHER BUSINESS:	All
11:15 – 12:30 pm	Novartis Pipeline – Closed	
12:30 – 1:00 pm	Melanoma Executive DSC Meeting – Closed	
	Meeting Adjourned	